Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Caribou’s allogeneic Car meets a six-month bar
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.